<DOC>
	<DOC>NCT01332604</DOC>
	<brief_summary>This is an open-label, multicenter, Phase Ib, dose-escalation study designed to assess the safety, tolerability, and pharmacokinetics of oral GDC-0980 administered in combination with capecitabine and with mFOLFOX6 chemotherapy with bevacizumab added on at Cycle 5 in patients with advanced or metastatic solid tumors.</brief_summary>
	<brief_title>GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Histologically or cytologically documented locally advanced or metastatic solid tumors for which established therapy is ineffective, not tolerable, or does not exist Patients with histologically or cytologically documented locally advanced or metastatic breast cancer who have received at least one prior chemotherapybased regimen for incurable disease (Arm A) Patients with histologically or cytologically documented locally advanced or metastatic CRC who have not received prior oxaliplatinbased therapy within 1 year of initiation of study treatment. (Arm B) Prior anticancer therapy that fulfills the following criteria: a total of more than six courses of an alkylating agent, a total of more than four courses of carboplatincontaining chemotherapy regimens, and a total of more than two courses of nitrosoureas or mitomycin C, highdose chemotherapy requiring stemcell support, and irradiation to &gt;= 25% of bone marrowbearing areas Current dyspnea at rest because of complications of advanced malignancy or other disease requiring continuous oxygen therapy Known deficiency of dihydropyrimidine dehydrogenase (DPD) Bisphosphonate therapy for symptomatic hypercalcemia Known untreated or active central nervous system (CNS) metastases Pregnancy, lactation, or breastfeeding For Arm B: Inadequately controlled hypertension Prior history of hypertensive crisis or hypertensive encephalopathy History of myocardial infarction or unstable angina within 6 months prior to the first dose of study treatment History of stroke or transient ischemic attacks within 6 months prior to the first dose of study treatment Significant vascular disease within 6 months prior to the first dose of study treatment History of hemoptysis within 1 month prior to the first dose of study treatment Patients with one or more pulmonary tumor masses with evidence of cavitation Evidence of bleeding diathesis or significant coagulopathy Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to the first dose of study treatment History of abdominal fistula, GI perforation, or intraabdominal abscess within 6 months prior to the first dose of study treatment Clinical signs or symptoms of GI obstruction or requirement for parenteral hydration, parenteral nutrition, or tube feeding Evidence of abdominal free air not explained by paracentesis or recent surgical procedure Serious, nonhealing wound, active ulcer, or untreated bone fracture The presence of an ulcerating breast cancer tumor will not render a patient ineligible Proteinuria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>